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Abstract 
The aminosalicylate mesalazine (mesalamine) forms the mainstay of treatment in ulcerative 
colitis (UC); a disease for which many commercial modified-release products have been 
developed with the aim of providing targeted gastrointestinal release. The release profiles of 
five of these commercial formulations were evaluated in bicarbonate buffer using a novel 
dissolution model that mimics the dynamic conditions of the gastrointestinal tract. Monolithic 
and multi-particulate mesalazine formulations with pH-dependent and/or independent 
release mechanisms were evaluated (Asacol® 800, Octasa®, Mezavant® XL, Salofalk®, 
Pentasa®), and each of the products displayed a distinctive dissolution profile. The 
dissolution results for Mezavant® XL (Lialda®) (lag time 290 min) demonstrated good 
correlation with previously reported in vivo disintegration times assessed by gamma-
scintigraphy in humans. Octasa® showed a similar lag time to Mezavant® XL. Drug release 
from Asacol® 800 (Asacol® HD) showed a wide standard deviation, reflecting the great 
variability in vivo. Salofalk® displayed both delayed release and extended release 
characteristics. Pentasa® released more than 50% of its drug load in the stomach 
compartment of the model, which is attributed to the absence of a gastro-resistant coating in 
this product. The new dissolution method provided a realistic and discriminative in vitro 
assessment of mesalazine release from different formulations. These results demonstrate 
that this strategy can be used to predict intestinal release behaviour, and potentially aid the 
rational design of products developed to target different sites of the gut. 
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Introduction  
Ulcerative colitis (UC) is one of two main entities of inflammatory bowel disease (IBD): 
Whereas Crohn’s disease is characterised by transmural inflammation and can manifest at 
any membranous site along the length of the gastrointestinal (GI) tract, inflammation in UC is 
strictly limited to the colonic and rectal gastrointestinal mucosa. UC is also a prevalent 
example of a GI disorder for which oral drug delivery methods have been developed and 
adapted specifically with a view to minimising the risk of associated adverse drug effects, 
and to more specifically target the disease site(s) (McConnell et al., 2009).  
Treatment strategies in UC are generally dominated by the use of aminosalicylates, with 
mesalazine - also known as mesalamine or 5-aminosalicylic acid (5-ASA) - as the first-line 
treatment indicated for UC. The exact mechanism of action of mesalazine has yet to be fully 
elucidated, though it is thought to act topically from the intestinal lumen to target proliferation 
and activity of inflammatory mediators such as prostaglandins. In this way, inflammatory 
“trafficking” and free radical production at disease-afflicted site(s) are considerably reduced 
(McConnell et al., 2009).  
Following oral administration, mesalazine is normally rapidly and extensively absorbed in the 
upper GI tract (Lichtenstein and Kamm, 2008). Consequently, the most commonly-used 
dosage forms are modified-release formulations of mesalazine. These formulations employ 
various strategies for drug delivery by the use of pH-sensitive and/or insoluble polymers 
intended to allow for release of drug into the lower confines of the gut. Feagan et al. (2013) 
recently reported that all mesalazine formulations are safe and effective in the treatment of 
mild to moderate ulcerative colitis, however, there is evidence that patients who demonstrate 
inadequate response to one type of formulation benefit from switching to a different type 
(Yoshimura et al., 2013). This may be related to the fact that the various formulations display 
differences in their drug release profiles (Fadda et al., 2009; Klein et al., 2005; Schellekens 
et al., 2007). The choice of mesalazine therapy is also often based on trial and error, due to 
difficulties in tailoring individual doses to patients in addition to effective targeting of the 
region(s) of the gastrointestinal tract affected by disease without resulting in premature drug 
release (Goyanes et al., 2015a; McConnell et al., 2009). 
Like all oral drug products, these mesalazine formulations are evaluated in human 
pharmacokinetic studies as well as clinical efficacy studies, though there is merit in 
developing an accurate in vitro model which best represents conditions in the human GI 
tract. Such a model would reduce both costs and development times through allowing early 
evaluation and comparison of the release profiles of various formulations simultaneously and 
in real time, as well as providing robust in vitro-in vivo correlations (IVIVCs).  
Indeed, the design of dissolution media to accurately reflect conditions in humans and thus 
provide a good in vitro correlation to the in vivo situation has also been a long-standing goal 
for the dissolution testing of solid oral dosage forms (McAllister, 2010; Varum et al., 2013a). 
Compendial phosphate buffers have formed the mainstay of in vitro dissolution testing media 
over the years, though these systems is otherwise poorly representative of in vivo small 
intestinal fluid composition, leading to the rapid dissolution of enteric-coated dosage forms 
(Liu et al., 2009; Varum et al., 2013b). A promising alternative to the use of these standard 
phosphate buffers, however, are physiological bicarbonate buffers – bicarbonate being the 
main buffer species of human gastrointestinal luminal fluids (Fadda et al., 2009; Garbacz et 
al., 2013; Krieg et al., 2014)– which have been shown to better discriminate the behaviours 
of oral dosage forms and hence produce more accurate IVIVCs than their phosphate 
counterparts (Liu et al., 2011; Merchant et al., 2014).  
In this work, we have evaluated a recently-developed Auto pH SystemTM that provides a 
closely-correlated representation of various human GI parameters including pH, ionic 
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strength and buffer capacity employing a physiological bicarbonate buffer under dynamic 
intestinal conditions (Goyanes et al., 2015b; Merchant et al., 2012; Varum et al., 2014). We 
studied the feasibility of using the system to evaluate the dissolution behaviours of five 
commercial modified-release formulations of mesalazine. Each of the formulations herein 
features a slightly different release mechanism as intended for inflammatory bowel diseases.  
 
Materials and Methods  
Materials 
The salts for preparing the buffer solutions were obtained from VWR International Ltd 
(Poole, UK) and the commercial products of mesalazine tested in this study are as follows: 
Asacol® 800 mg MR tablets (Asacol® HD in USA) (Warner Chilcott UK Ltd., UK) is a tablet 
formulation with a double-layered enteric coating comprising Eudragit S (methacrylic acid – 
methyl methacrylate copolymers (1:2)) and Eudragit L (methacrylic acid – methyl 
methacrylate (1:1)) which have a dissolution pH threshold of 7 and 6 respectively. The inner 
coating is Eudragit S and the outer coating is a mixture of Eudragit S and L (Fadda et al., 
2009), however, the ratio of Eudragit S and L in the outer coat is not disclosed.  
 
Mezavant® XL 1200 mg tablets (Lialda® in USA) (Shire Pharmaceutical Ltd., UK) is a tablet 
formulation with a sustained release hydrophilic/lipophilic matrix core known as the Multi 
Matrix System® (MMX™) (Cosmo, Milan, Italy) and an outer enteric coating comprising 
Eudragit S and L, however, the ratio of Eudragit S and L is not disclosed.  
 
Octasa® 800 mg MR tablets (Tillotts Pharma UK Ltd, UK) is a tablet formulation coated with 
Eudragit S. 
Pentasa® 500 mg tablets (Ferring Pharmaceuticals Ltd., UK) are made of the compressed 
ethylcellulose coated granules, where drug release from granules is mediated by diffusion 
through the insoluble polymer coat. 
Salofalk® 500 mg granules (Apriso® 0.375g in USA) (Dr. Falk Pharma UK Ltd., UK) are 
gastric-resistant (Eudragit L® coated) granules, offering prolonged drug release from a matrix 
core centred on the pH-independent polymer, Eudragit NE.   
 
Methods 
Design and development of the physiological dynamic dissolution method  
Two physiological salt solutions predominately buffered by bicarbonate ions were modulated 
to exhibit the physiological intestinal pH following gastric emptying. The media are primarily 
a bicarbonate buffer in which bicarbonate (HCO3
-) and carbonic acid (H2CO3) co-exist in an 
equilibrium, along with CO2 (aq) resultant from the dissociation of the carbonic acid. The pH 
of the buffer system can be altered by adjusting the concentration of carbonic acid (H2CO3) 
and bicarbonate (HCO3
-), the conjugate base, according to the Henderson-Hasselbalch 
equation. pH can be decreased by purging CO2 (g) in the solution, which promotes the 
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formation of carbonic acid. Similarly, to decrease the carbonic acid (H2CO3) to bicarbonate 
(HCO3
-) ratio, an inert gas (such as Helium) is purged into the solution, which removes the 
dissolved CO2 from the solution and therefore reduces the concentration of carbonic acid, 
reducing the pH of the media. The purging of gases is controlled by an Auto pH SystemTM 
(Merchant et al., 2012), automatically triggered by a pH feedback from the dissolution vessel 
(Figure 1). The Auto pH SystemTM consists of a pH probe connected to a source of carbon 
dioxide gas (pH reducing gas), as well as to a supply of helium (pH increasing gas), 
controlled by a control unit. The control unit monitors changes in pH of the bicarbonate buffer 
and, as appropriate, feeds pH increasing and/or pH reducing gas from the supplies into the 
dissolution vessel. The control unit is able to provide a dynamically adjustable pH during 
testing (dynamic conditions) and to maintain a uniform pH value over the otherwise unstable 
bicarbonate buffer pH. Under dynamic conditions, the automated switching of the buffer pH 
between pre-defined set points allows the instrument to mimic the changing pH found in the 
gastrointestinal tract. Detailed information on the system can be found in Merchant et al., 
(2012).  
A two-tiered bicarbonate-based buffer was used in this study. Initially, a modified Hanks 
buffer (mHanks) based dissolution media (Liu et al., 2011) (950 mL) was used, which 
followed the gastric phase, for the first 35 min (136.9 mM NaCl, 5.37 mM KCl, 0.812 mM 
MgSO4.7H2O, 1.26 mM CaCl2, 0.337 mM Na2HPO4.2H2O, 0.441 mM KH2PO4, 4.17 mM 
NaHCO3). Subsequently, 50 mL of pre-Krebs solution (400.7 mM NaHCO3 and 6.9 mM 
KH2PO4) was added to each dissolution vessel which forms an in-situ modified Kreb’s 
(mKreb’s) buffer (Fadda et al., 2009). These media closely resemble the ionic composition 
and buffer capacity of the intestinal fluids (Fadda et al., 2009; Liu et al., 2011). The buffer 
capacity of the physiological bicarbonate buffers representing the upper small intestine, 
lower small intestine and colon (3.1, 3.4 and 13 mM/L/ΔpH respectively (Fadda et al., 2009; 
Liu et al., 2011)), closely matches the buffer capacity of the intestinal fluids collected from 
the upper small intestine, lower small intestine and colon of humans (3.2, 6.4 and 13 
mM/L/ΔpH respectively (Fadda et al., 2010)). 
 
Test conditions 
The drug release from the commercial formulations was tested using a USP-II apparatus 
(Model PTWS, Pharmatest, Hainburg, Germany). To replicate the conditions of the GI tract 
the tablets or granules were initially placed for 2 h into 750 mL of 0.1 M HCl; and 
subsequently into 950 mL of modified Hanks based dynamic physiological dissolution 
medium for 35 min (pH 5.6 to 7); then in mKrebs buffer (pH 7 to 7.4 and then to 6.5). The 2 h 
acid stage simulates the gastric residence time, the 3.5 h in bicarbonate buffer at pH 5.6 to 
7.4 represents the transit time through the small intestine, followed by a drop in buffer pH 
(6.5) which represents the colonic environment. These conditions were selected based on 
literature data to represent conditions for intestinal transit of pharmaceutical dosage forms 
and pH values in different segments of the GI tract in a “typical” fasted individual (Davis et 
al., 1986; Evans et al., 1988; Freire et al., 2011; Ibekwe et al., 2008a; McConnell et al., 
2008a; Nugent et al., 2001).  
The paddle speed was fixed at 50 rpm and the tests were conducted at 37 + 0.5 °C (n=6). 
The amount of mesalazine released from commercial formulations was determined using an 
in-line UV spectrophotometer (Cecil 2020, Cecil Instruments Ltd., Cambridge, UK) at the 
wavelength of 310 nm for samples from the acid media and of 330 nm for those in 
bicarbonate buffer media. Data were processed using Icalis software (Icalis Data Systems 
Ltd, Berkshire, UK).  
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Results and discussion 
The physiological bicarbonate based dynamic dissolution media showed a high control of the 
pH (±0.01 pH units) using the Auto pH SystemTM. The pH was controlled within the range of 
pH 5.6 to 7.4, and it was subsequently decreased to a value of pH 6.5 in order to simulate 
the dynamic pH conditions of the small and large intestines. Figure 2 shows a real-time pH 
profile achieved with the use of the Auto pH SystemTM at the various set points to modulate 
the pH of the media to resemble a typical fasted state GI transit and pH profile. 
  
The drug release performance of the mesalazine products is depicted in Figure 3. All four 
enteric coated formulations were resistant to acid, showing no drug release after 2 h of 
exposure to 0.1 M HCl. In the intestinal phase of the test, release from the enteric coated 
products was dependent on the nature of the pH-dependent coating material. The 
physiological pH trigger of the Salofalk® product under the test conditions is 7.2. For the 
Asacol®, Octasa® and Mezavant® products the pH trigger is 7.4, but the lag times for release 
differ for each product. For all the enteric coated products, drug release is initiated in the 
small intestinal phase of the test and then continues in the colonic compartment of the test 
(after 330 mins). In contrast to the enteric coated formulations, in the case of Pentasa more 
than 50% of the drug load was released after 2 h of exposure to acid. 
 
Though limited by their inability to simulate complex aspects of GI physiology, there is much 
merit in developing effective and accurate in vitro models for the purpose of mimicking 
physiological conditions in human for mesalazine products. The true value of these models 
also lies in enabling extrapolation of real-time data on dissolution and distribution kinetics to 
inform both preclinical and clinical studies – information otherwise not readily derived from 
other techniques such as gamma scintigraphy, pharmacokinetic studies and gut mucosal 
biopsies (Lichtenstein and Kamm, 2008).  
As such, the dynamic dissolution system has successfully discriminated the intestinal 
release behavior of the five mesalazine products. In the case of Mezavant® XL, the 
dissolution results using bicarbonate buffer under the dynamic mode correlated closely with 
the in vivo disintegration times of the same product from Wray et al. (2008), as assessed by 
gamma-scintigraphy in humans. The in vitro lag time under the dynamic conditions for 
Mezavant® XL in this study was 290 min, which correlates well with the initial tablet 
disintegration time of the same formulation in vivo (lag time 285 min). The gastroresistant 
coating of Mezavant® XL– which is a mixture of Eudragit S and L polymers – is designed to 
allow dosage form transportation to the lower gut by circumventing the harsh acidic 
conditions of the stomach. It is the core of Mezavant® XL which is purported to extend 
release of drug by formation of an outer viscous gel mass on contact of the exposed core to 
fluid following dissolution of the coating. However, our results have shown that the release 
profile of mesalazine from this formulation was similar to that of the other pH 7-coated 
tablets with no apparent evidence of superior sustained release characteristics. This 
phenomenon was also demonstrated in a study by Fadda et al, (2009) whereupon both the 
lag times and drug release profiles for Mezavant® XL were shown to display different 
behaviours in Krebs buffer as compared to phosphate buffer, with no slow release in Krebs 
bicarbonate media.  
 
By comparison, the formulations Asacol® and Octasa® showed slightly different lag times - 
240 and 330 min respectively (Figure 3). The early onset of release observed for Asacol® by 
comparison to Octasa® may be explained by the difference in composition of the their 
gastro-resistant coatings. The enteric coat of Octasa® is the Eudragit S polymer, which 
dissolves at pH 7. By contrast, Asacol® comprises two enteric coatings; the inner coating is 
an Eudragit® S polymer, whereas the outer coating is a blend of Eudragit® S and L (Fadda et 
al., 2009). The high standard deviation of Asacol® also indicates an expected high variability 
in vivo (eMC-Asacol). Overall, according to the drug dissolution profiles for these products 
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obtained under these standard fasted state conditions, release in vivo would take place in 
the last part of the small intestine and continue into the colon.  
An issue with these, and similar preparations, is that a failure to disintegrate has been 
reported with some dosage forms in vivo. This dosage form failure might be expected in 
inflammatory bowel disease patients (IBD) in whom the colonic pH may be lower. pH values 
of 4.7 ± 0.72 were measured in the right colon of ulcerative colitis patients (Nugent et al., 
2000), and a fall in colonic pH to <5.5 was found in 2 out of 6 patients studied (Fallingborg et 
al., 1993). In one case, a proximal colonic pH as low as 2.3 was detected in an ulcerative 
colitis patient (Fallingborg et al., 1993). However, the failure to disintegrate was also 
observed in healthy volunteers (McConnell et al., 2009). This led to the suggestion that pH-
responsive dosage forms are influenced by more than just pH (Ibekwe et al., 2008b), but 
also by residence time at the ileocaecal junction and feeding states. Gastrointestinal fluid 
composition is also important as the mechanism of enteric polymer dissolution in aqueous 
fluids is complex and influenced by a multitude of factors (Narasimhan and Peppas, 1997; 
Nguyen and Fogler, 2005). Hydrogen ions are generated at the polymer-solution interface 
during polymer dissociation (Nguyen and Fogler, 2005) and contribute to a pH drop near the 
surface of the dissolving carboxylic polymer (Harianawala et al., 2002). Removal of these 
hydrogen ions at the interface increases the polymer dissolution rate, and can be facilitated 
by reacting with proton acceptors (buffer species) depending on their buffer capacities, 
which also directly linked to the pKa of the buffering species. The rank order in the 
dissolution of these products can be explained by the determinant factors for enteric coating 
dissolution; that is, polymer pKa and chemical structure (Ozturk et al., 1988). Polymers with 
higher pKa values reflected by higher dissolution pH thresholds include the Eudragit® S100 
coated product, Octasa® 800, which had slower drug release. 
 
To circumvent some of the issues above, other approaches to pH-responsive drug delivery 
to the distal gut include using polymers that have a lower pH threshold. In this respect for 
Salofalk® 500mg granules, the release of drug begins in the small intestine after 195 min – 
much earlier than for the other aforementioned products (Figure 3). This is supported by 
pharmacokinetic data where Salofalk® product displays a shorter time to maximum plasma 
concentration - 4- 5 h (eMC-Salofalk) - than the other enteric products, Asacol® 4-12 h 
(eMC-Asacol) or Mezavant® 9-12 h (eMC-Mezavant). The shorter lag time is attributable to 
the fact that the coating of Salofalk® is based on the polymer Eudragit L, which has a 
theoretical pH threshold of 6. At this value, no release occurs, but instead only begins with a 
lag time delayed until pH 7.2 is achieved (~175 mins). Salofalk® is thus advantageous in 
potentially overcoming the “pass-through” effects noted with the other comparable 
formulations. However, enteric coated pellets have also been observed to pass through the 
gut intact (McConnell et al., 2008b). Although this approach of delayed and sustained drug 
release throughout small and large intestine is not very efficacious in targeting colon in 
ulcerative colitis but can be advantageous in patients with inflamed sites spread across the 
gut. 
In contrast to the pH dependent release systems, the Pentasa® product is manufactured with 
a pH independent polymer (ethylcellulose), in consequence, the Pentasa® formulation 
evaluated in this study showed distinctly different behaviour in terms of its drug release as 
compared with the others formulations. Pentasa® 500 mg tablets are comprised of 
compressed ethylcellulose-coated granules that degranulate rapidly in the acid stage. The 
drug release mechanism in this case is by diffusion through this insoluble polymer, allowing 
for more than 50% of drug release to take place during the acid stage with the subsequent 
50% releasing throughout the entire small intestine and colon (Figure 3). Interestingly, the 
mucosal concentrations of mesalazine in the sigmoid colon is lower from this type of pH 
independent formulations compared to those receiving pH dependent formulations (D'Inca et 
al., 2013).  
The physiologic dissolution system evaluated in this study can be theoretically modified to 
mimic different situations (real-life) such as transit time, fluid volumes and pH values; and it 
could be further improved by the addition of other luminal compounds including 
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acetate/maleate and short chain fatty acids which are found in the last part of the gut. It may 
also be possible to mimic the environment of different disease states that we know have 
different GI profiles to otherwise “normal” healthy individuals. Indeed, this can be crucial for 
the drug release from dosage forms designed to dissolve at a specific pH value which may 
only be maintained in the gut for a short amount of time in a given individual, and thus be 
potentially insufficient to allow for complete drug release. Such variations may also be 
apparent in disease states such as IBD, manifesting as diarrhoea and affecting the 
performance of modified release formulations. Whereas, altering various parameter values 
of the in vitro physiologic model – including pH and residence times – may also render it 
possible to evaluate robustness of these different products under different conditions.  
 
Conclusions 
The dynamic dissolution system provides a realistic in vitro simulation of the gastrointestinal 
tract. This system provided discriminative in vitro assessment for various commercial 
modified-release mesalazine formulations all run under an identical set of standard 
conditions reflecting typical in vivo transit and pH conditions. We have shown that the 
release profiles of five commercial formulations of mesalazine – Asacol® 800 mg tablets, 
Mezavant® XL 1200 mg tablets, Octasa® 800 mg tablets, Pentasa® 500 mg tablets and 
Salofalk® 500 mg granules - differ considerably. These differences can be attributed to the 
different mechanisms used to control/modified the release of mesalazine, but owing to the 
highly variable physiological conditions of the GI tract, suggests that the release of drug may 
equally be compromised by factors such as inter-individual variability. One of the main 
highlights of the study was identifying good correlation (both in vitro and in vivo lag times) for 
drug release from the Mezavant® XL product specifically, supporting the notion that the novel 
dissolution testing approach can be used as a predictive tool of in vivo results. Altering the 
settings of the in vitro physiologic model – including pH and residence times – may also 
render it possible to evaluate robustness of these different products under different 
conditions, for instance simulating disease states such as IBD, manifesting as diarrhoea and 
affecting the performance of modified release formulations.  
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Figure captions 
Figure 1. Schematic design of the Auto pH SystemTM used to modulate and maintain the pH 
of a bicarbonate buffer in a conventional USP-II apparatus. Figure adapted from Merchant et 
al., 2012. 
Figure 2. A real-time pH profile of a bicarbonate based dissolution media simulating the 
dynamic pH conditions of the gut in a conventional USP-II apparatus employed for 
dissolution testing. The pH was modulated and maintained using the Auto pHTM System.  
Figure 3. Drug release from the commercial formulations in 0.1M HCl for 2h followed by 
physiological bicarbonate buffer under dynamic pH conditions (pH ramp from 5.6 to 7.4 
followed by a drop to pH 6.5) controlled by the Auto pH SystemTM. Red line shows real-time 
pH dissolution values. 
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